Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BouNDless trial of continuous subcutaneous ND0612 versus oral immediate-release levodopa/carbidopa in Parkinson's disease with motor fluctuations
NL-OMON52856Phase 3Recruiting
- Sponsor
- NeuroDerm Ltd.
- Start
- Nov 2020
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ND0612 in Parkinson's disease (PD) (2 arms), sponsored by NeuroDerm Ltd. Primary endpoint: Change in mean daily good ON time at DB week 12. Started Nov 2020; status: recruiting.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON52856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52856.